1H-吡唑并[1,5-a]吲哚 | 42318-55-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1H-吡唑并[1,5-a]吲哚
• 英文名称: 1h-Pyrazolo[1,5-a]indole
• CAS: 42318-55-8
• 化学式: C₁₀H₈N₂
• mdl: MFCD18809760
• 分子量: 156.18
• InChiKey: SDASQSBLIWRQLJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  0

文献信息

• COMPOUNDS FOR TREATMENT OF HEART FAILURE
  申请人：Gilmer John

  公开号：US20130338118A1

  公开（公告）日：2013-12-19

  A combination of: a first tetracycline (TC) component; and a second component capable of releasing nitric oxide (NO) or a nitrate capable of mimicking NO effects in vivo (NO mimetic). The combinations of the invention advantageously act as more effective MMP modulators with selective reductions in circulating MMP-9 levels in-vivo and inhibitory effects on MMP-2 and MMP-9 levels in-vitro. The combinations of the invention also advantageously act as modulators of inflammation mediators. The co-existence of abnormalities of MMP enzymes and inflammation in many diseases make these characteristics advantageous. Therefore, the various combinations of the invention find utility in medical applications where MMPs and/or inflammation is implicated.

  一种组合物：第一四环素（TC）成分；和第二成分，能释放一氧化氮（NO）或模拟体内NO效应的硝酸盐（NO类似物）。本发明的组合物有利地作为更有效的MMP调节剂，在体内选择性降低循环MMP-9水平，并在体外对MMP-2和MMP-9水平产生抑制作用。本发明的组合物还有利地作为炎症介质的调节剂。在许多疾病中MMP酶和炎症的异常共存使这些特性具有优势。因此，本发明的各种组合物在MMP和/或炎症参与的医学应用中具有用途。
• Treatment of refractory cancers using Na+/K+-ATPase inhibitors
  申请人：Khodadoust Mehran

  公开号：US20080027010A1

  公开（公告）日：2008-01-31

  The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na + /K + -ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.
• Uses of Kinase Inhibitors and Compositions Thereof
  申请人：Caligiuri Maureen G.

  公开号：US20080146555A1

  公开（公告）日：2008-06-19

  The invention pertains to inhibitors of various kinases (e.g. S/T kinases, Tyr kinases, etc.), which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). As described herein, the inhibitors of this invention are capable of inhibiting various wild-type and mutant form kinases, including drug resistant forms of mutant kinases. Thus the subject kinase inhibitors are useful in treating a wide range of diseases/conditions associated with abnormal functions/excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors and patients which are resistant or refractory to other therapeutic agents. Pharmaceutical compositions and packaged pharmaceuticals with instructions of these inhibitors, and methods of using these inhibitors are also provided.
• Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane
  申请人：Wosikowski-Buters Katja

  公开号：US20090030067A1

  公开（公告）日：2009-01-29

  The present invention describes a method of prevention and/or treatment of a cancer or a tumor, and in particular a combination therapy, methods, compositions and pharmaceutical packages comprising a taxane and certain platinum-based chemotherapeutic agents.
• Anti-Proliferative Combination Therapy Using Certain Platinum-Based Chemotherapeutic Agents and EGFR Inhibitors or Pyrimidine Analogues
  申请人：Wosikowski-Buters Katja

  公开号：US20090175856A1

  公开（公告）日：2009-07-09

  The present invention describes a method or uses of prevention and/or treatment of a cancer or a tumor, and in particular to a combination therapy, methods, compositions and pharmaceutical packages comprising an inhibitor of receptors of the EGFR family or a chemotherapeutically active pyrimidine analogue and certain platinum-based chemotherapeutic agents.